Become a member of BioTechniques (it's free!) and receive the latest news in the life sciences and member-exclusives.

Challenging the ‘art’ of SPR

Real-time, label-free binding analysis is often viewed incorrectly as an ‘art’ instead of a ‘science’. The Octet® SF3 system challenges this notion through user-friendly technology.

The field of real-time, label-free SPR protein-binding analysis has historically been marked with steep learning curves and can often seem daunting to new or inexperienced users, being viewed as an ‘art’ instead of a ‘science’ due in part to the lack of exposure to the technique.

The Octet® SF3 SPR system contains a unique injection method called OneStep® that simplifies the process of choosing the correct analyte concentration. It allows users to generate accurate kinetics and affinity values from a single analyte concentration, saving a substantial amount of time on assay development and assay performance compared to standard SPR methods.

 

What will you learn?Who may this interest?Speaker
  • How to unpick the ‘art’ of SPR
  • How to design and develop successful SPR assays
  • The benefits of OneStep® injections compared to standard multi-cycle kinetics
  • How to rapidly optimize analyte concentrations to determine accurate kinetics and affinity
  • How your current SPR assays can be successfully transferred to the Octet® SF3 system
  • Lab Director, Lab Manager, Research Assistant, Graduate Student, Postdoctoral Fellow, Research Scientist
  • Assay Development, Protein Analysis, Label-free Quantification
  • Private Research, Contract Research, Biopharmaceutical, Biotech, University

Speaker

Stuart Knowling

Senior Application Scientist

Sartorius (Göttingen, Germany)

Stuart Knowling has over a decade of experience in surface plasmon resonance (SPR) combined with almost twenty years’ worth of experience in biophysical protein and nucleic acid production and characterization.
Using SPR-based technologies, Stuart has initiated and developed multiple assay formats to characterize biosimilar monoclonal antibody-based therapies as part of larger similarity studies. Stuart also has a strong focus on developing target-binding assays across a range of protein and non-protein molecules to meet the needs of his clients at all stages of submission to regulatory bodies.
Stuart is highly active in presenting his work across the globe and is the lead author on multiple SPR guidelines, continuing to advance Octet® SPR by Sartorius so that users can generate high-quality data in the simplest manner possible.

 

In association with

This webinar was recorded on Thursday 9 November 2023